Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Saved in:
Main Authors: | Sarah Costa (Author), Colene Bentley (Author), Dean A. Regier (Author), Helen McTaggart-Cowan (Author), Craig Mitton (Author), Michael M. Burgess (Author), Stuart J. Peacock (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada
by: Colene Bentley, et al.
Published: (2018) -
Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy
by: Colene Bentley, et al.
Published: (2019) -
Describing practices of priority setting and resource allocation in publicly funded health care systems of high-income countries
by: Brayan V. Seixas, et al.
Published: (2021) -
Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
by: Julie Polisena, et al.
Published: (2017) -
The impact of the COVID-19 pandemic on health-related quality of life of cancer patients in British Columbia
by: Sara Izadi-Najafabadi, et al.
Published: (2024)